Pre-made Datopotamab benchmark antibody ( Whole mAb, anti-TACSTD2 therapeutic antibody, Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Datopotamab biosimilar, Whole mAb, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Datopotamab deruxtecan is an antibody drug conjugate (ADC), composed of an humanised anti-TROP2 monoclonal antibody and MAAA 1181a, a derivative of exatecan, a DNA topoisomerase I inhibitor, being developed by Daiichi Sankyo for the treatment of solid tumours including non-small cell lung cancer and breast cancer .

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-134-1mg	1mg	3090
GMP-Bios-ab-134-10mg	10mg	Inquiry
GMP-Bios-ab-134-100mg	100mg	Inquiry
GMP-Bios-ab-134-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Datopotamab biosimilar, Whole mAb, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody
INN Name	Datopotamab
Target	TACSTD2
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Daiichi Sankyo
Conditions Approved	na
Conditions Active	Breast cancer;Non-small cell lung cancer
Conditions Discontinued	na
Development Tech	na